Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications
Frontiers in Pharmacology · 04.06.2026 · 17
DOI: 10.3389/fphar.2026.1828829 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.06.2026. Verfasst von Meidan Ding und 2 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Xinhua Hospital of Dalian University, Dalian, China. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ovarian cancer, one of the most common gynecological malignancies, ranks as the fifth leading cause of cancer death in women. To investigate the mechanism by which isoliquiritigenin (ISL) regulates the JAK/STAT signaling pathway in ovarian cancer intervention, this review integrates cellular, animal, and preclinical studies on ISL treatment for ovarian cancer, explores how ISL modulates the JAK/STAT pathway and affects ovarian cancer cell behavior and the tumor immune microenvironment, and summarizes the related mechanisms and research progress. The results show that ISL exerts significant anti-ovarian cancer effects through multitarget regulation of the JAK/STAT pathway. With the advantages of low toxicity and multi-pathway modulation, ISL is a promising natural candidate for targeted therapy, reversal of drug resistance, and combination therapy in ovarian cancer, thus holding great value for basic research and clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Xinhua Hospital of Dalian University, Dalian, China.
Zitieren
APA
Ding, M., Guo, F., & Lin, P. (2026). Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1828829
Vancouver
Ding M, Guo F, Lin P. Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1828829
BibTeX
@article{Ding2026,
author = {Ding, Meidan and Guo, Fangfang and Lin, Ping},
title = {Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1828829}
}
EUVIMED